Skip Main Navigation | Skip to Content

An expensive and complicated journey

 Bringing a new drug to market is one of the most difficult propositions in science — partly because so much of the process takes place outside the lab.
“It’s not something we are taught in school,” said College of Medicine neuroscientist Pradeep Bhide, who has spent nearly 10 years developing a novel treatment for attention deficit hyperactivity disorder.
With support from Florida State University, Bhide created a startup company, Avekshan LLC, in 2012 as a first step into the business of developing a new drug. As with any similar startup company, Avekshan faced one particularly challenging problem. Synthesizing a drug and gaining Food and Drug Administration approval based on animal and human toxicity studies and clinical trials is a multiyear proposition costing millions of dollars.

Additional Information